Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 31 2023 - 3:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
FORM
12b-25 |
SEC
FILE NUMBER
000-55144 |
|
NOTIFICATION
OF LATE FILING |
CUSIP
NUMBER
__________ |
(Check one): |
☒ Form
10-K ☐ Form
20-F ☐ Form
11-K ☐ Form
10-Q ☐ Form
10-D
☐ Form
N-CEN ☐ Form
N-CSR |
|
|
|
For Period Ended: December 31, 2022
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
For the Transition Period Ended: ____________________ |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
NUTRALIFE
BIOSCIENCES, INC.
Full
Name of Registrant.
Former
Name if Applicable
6601
Lyons Road, Suite L-6
Address
of Principal Executive Office (Street and Number)
Coconut
Creek, FL 33073
City,
State and Zip Code:
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
|
|
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period. (Attach extra Sheets if Needed).
NutraLife
BioSciences, Inc. (the “Company”) has determined that it is unable to file its Annual Report on Form 10-K for the year ended
December 31, 2022 (the “Form 10-K”) by March 31, 2023, the original due date for such filing, without unreasonable effort
or expense because it requires additional time to complete its financial statements. This delay principally relates to the fact that
the Company needed additional time to compile information required for the audit and accordingly the auditors need additional time to
complete the audit. The Company expects that it will file the Form 10-K no later than the fifteenth calendar day following the prescribed
filing date.
PART
IV — OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
Edgar
Ward |
|
888 |
|
509-8901 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). |
|
Yes
☒ ☐ |
|
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
|
Yes
☐ No ☒ |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
NUTRALIFE
BIOSCIENCES, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: |
March
31, 2023 |
|
By: |
/s/
Edgar Ward |
|
|
|
|
Edgar
Ward
Chief
Executive Officer |
NutraLife Biosciences (CE) (USOTC:NLBS)
Historical Stock Chart
From Nov 2024 to Dec 2024
NutraLife Biosciences (CE) (USOTC:NLBS)
Historical Stock Chart
From Dec 2023 to Dec 2024